U
Ultragenyx Pharmaceutical
Treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases
At a glance
- Status
- Listed
- Listing
- IPO 2014
- Outcome tier
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Open roles
Ultragenyx Pharmaceutical in the Novato ecosystem
The Ultragenyx Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- TVTakeda Ventures
TPG
Series B and later5 investors entered at this stage
- PCPappas Capital
- HEHealthCap
RA Capital Management
F-Prime- TGTPG Growth
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
50 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Ultragenyx Pharmaceutical was the backer or acquirer, 2017–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
4 deals across Ultragenyx Pharmaceutical's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Ultragenyx Pharmaceutical's portfolio, mapped.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ultragenyx Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ultragenyx Pharmaceutical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


FDA approves Ultragenyx's FAYUVI, first-ever treatment for Sanfilippo syndrome type A
Ultragenyx's Angelman syndrome drug fails pivotal Phase 3 trial
Ultragenyx lands FDA approval for GENGLYCOS, first gene therapy for glycogen storage disease type Ia